Tag: EMA

International Perspectives on NTI Generics: Regulatory Approaches Compared

NTI generics require stricter regulation than standard generics due to their narrow safety margin. This article compares how the FDA, EMA, Health Canada, and Japan regulate these high-risk drugs, highlighting differences in bioequivalence standards, substitution rules, and market dynamics.